Showing 3991-4000 of 8849 results for "".
- Aclaris Therapeutics Receives US Patent Covering a JAK Inhibitor for Treating Hair Loss Disordershttps://practicaldermatology.com/news/aclaris-therapeutics-receives-us-patent-covering-a-jak-inhibitor-for-treating-hair-loss-disorders/2457840/The United States Patent and Trademark Office (USPTO) issued US Patent No. 9,895,301, which is directed to methods related to the use and administration of a certain janus kinase (JAK) inhibitor for treating hair loss disorders. This newly allowed patent is owned by The Trustees of Columbia Unive
- Sensus Healthcare Launches New Line of Laser Systems for Clinical and Aesthetic Dermatologyhttps://practicaldermatology.com/news/sensus-healthcare-launches-new-line-of-laser-systems-for-clinical-and-aesthetic-dermatology/2457846/Sensus Healthcare, Inc. has launched Sensus Laser Systems, a unique multi-platform line of high-quality, cost-effective dermatological lasers to complement its existing superficial radiation therapy (SRT) system, which is used for non-invasive treatment of non-melanoma skin cancers and keloids. T
- Study: PsO, RA Patients Prescribed Similar Drugs, But PsO Patients Face Higher Liver Disease Riskhttps://practicaldermatology.com/news/study-pso-ra-patients-prescribed-similar-drugs-yet-pso-patients-face-higher-liver-disease-risk/2457987/Compared to controls, patients with psoriasis (PsO) are at higher risk for serious liver disease than patients with rheumatoid arthritis, reports a in the Journal of Investigative Dermatology from researchers a
- Sensus Healthcare Launches SRT-100 for Keloid Prevention and Treatment in Chinahttps://practicaldermatology.com/news/sensus-healthcare-launches-srt-100-in-china-for-keloid-prevention-and-treatment/2457985/Sensus Healthcare, Inc. launched the SRT-100™ in China for the treatment and prevention of keloids with Chindex Medical Limited. Sensus also announced the extension of its exclusive distribution agreement with Chindex M
- Use of a New Holographic Hand Piece May Improve Picosecond Laser Treatment of Acne Scarshttps://practicaldermatology.com/news/study-adding-a-holographic-beam-splitter-to-picosecond-laser-improves-acne-scars/2457993/Incorporating a new holographic beam splitter in a picosecond laser may help improve the appearance of acne scars, according to a study published in Lasers in Surgery and Medicine (LSM). The paper was selecte
- Sun Dermatology Launches Absorica Tracker App to Help Patients Track Progresshttps://practicaldermatology.com/news/sun-dermatology-launches-absorica-tracker-app-to-help-patients-track-progress/2457999/Sun Pharma launched an Absorica Tracker App to help patients get the most out of their treatment. The easy-to-use interface is designed to help users to monitor their progress with Absorica (isotretinoin) treatment with features like medication and appointment reminders, monthly tips and checklis
- Warning: Sindoor Used in Hindu Ceremonies May Contain Unsafe Lead Levelshttps://practicaldermatology.com/news/warning-sindoor-used-in-hindu-ceremonies-may-contain-unsafe-lead-levels/2458037/Sindoor – a cosmetic powder sold in the United States and used during Hindu religious and cultural ceremonies – may contain unsafe levels of lead, Rutgers University researchers warn. Researchers from the School of Public Health reported that 83 percent of the samples collecte
- Histogen's Growth Factor Technology Now Part of Allergan's Skin Care Linehttps://practicaldermatology.com/news/histogens-growth-factor-technology-now-part-of-allergan-skin-care-line/2458111/Histogen’s growth factor technology will be marketed as part of Allergan's skin care line within its recently acquired Regenica® Advanced Rejuvenation System. The Regenica line is based on multipotent CCM Complex (Cell Conditioned Media) which comprises active growth factors
- FDA Clears Philips BlueControl Wearable Light Therapy Device to Treat Mild Psoriasis At Homehttps://practicaldermatology.com/news/fda-clears-philips-bluecontrol-wearable-light-therapy-device-to-treat-mild-psoriasis-at-home/2458124/The FDA has granted Royal Philips 510(k) clearance to market the Philips BlueControl wearable light therapy device to treat mild psoriasis. In the US, BlueControl is a Class II prescription medical device designed for home use. Clinical studies have demonstrated that the UV-free blue LED
- FOREO's New At-Home Blue Light Acne Pen Hits the US and Canadahttps://practicaldermatology.com/news/foreos-new-at-home-blue-light-acne-pen-hits-the-us-and-canada/2458129/FOREO's blue-light acne pen is now available in 333 stores in the US and Canada with more to be added by September 2017. The FOREO ESPADA comprises 415 nanometers (nm) of blue light energy combined with red cross-hair targeting that converges as ESP